These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38148755)

  • 1. Potentiality of bioactive compounds as inhibitor of M protein and F protein function of human respiratory syncytial virus.
    Mitra D; Paul M; Thatoi H; Das Mohapatra PK
    In Silico Pharmacol; 2024; 12(1):5. PubMed ID: 38148755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Threat of respiratory syncytial virus infection knocking the door: a proposed potential drug candidate through molecular dynamics simulations, a future alternative.
    Mitra D; Afreen S; Das Mohapatra PK; Abdalla M
    J Mol Model; 2023 Mar; 29(4):91. PubMed ID: 36884131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of Cross-Resistance to Fusion Inhibitors Conferred by the K394R Mutation in Respiratory Syncytial Virus Fusion Protein.
    Tang W; Li Y; Song Q; Wang Z; Li M; Zhang Q; Wang Y; Ye W; Li Y
    J Virol; 2021 Sep; 95(20):e0120521. PubMed ID: 34379500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico virtual screening of lead compounds for major antigenic sites in respiratory syncytial virus fusion protein.
    Mathew S; Taleb S; Eid AH; Althani AA; Yassine HM
    Emergent Mater; 2022; 5(2):295-305. PubMed ID: 33969268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
    Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
    Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Respiratory Syncytial Virus Mechanism of
    Du H; Ding J; Wang P; Zhang G; Wang D; Ma Q; Li N; Sun T
    Comb Chem High Throughput Screen; 2021; 24(8):1137-1150. PubMed ID: 32957876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
    Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Murine Pneumonia Virus Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus from an Added Gene Is Highly Attenuated and Immunogenic in Rhesus Macaques.
    Brock LG; Liu X; Liang B; Lingemann M; Liu X; Herbert R; Hackenberg AD; Buchholz UJ; Collins PL; Munir S
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Respiratory Syncytial Virus Infection on Host Functions: Implications for Antiviral Strategies.
    Hu M; Bogoyevitch MA; Jans DA
    Physiol Rev; 2020 Oct; 100(4):1527-1594. PubMed ID: 32216549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.
    Mackow N; Amaro-Carambot E; Liang B; Surman S; Lingemann M; Yang L; Collins PL; Munir S
    J Virol; 2015 Oct; 89(20):10319-32. PubMed ID: 26223633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection.
    Liang B; Munir S; Amaro-Carambot E; Surman S; Mackow N; Yang L; Buchholz UJ; Collins PL; Schaap-Nutt A
    J Virol; 2014 Apr; 88(8):4237-50. PubMed ID: 24478424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
    Patel N; Massare MJ; Tian JH; Guebre-Xabier M; Lu H; Zhou H; Maynard E; Scott D; Ellingsworth L; Glenn G; Smith G
    Vaccine; 2019 Sep; 37(41):6112-6124. PubMed ID: 31416644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
    Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational redesign of human respiratory syncytial virus epitope as therapeutic peptide vaccines against pediatric pneumonia.
    Shi X; Zheng J; Yan T
    J Mol Model; 2018 Mar; 24(4):79. PubMed ID: 29500665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A critical phenylalanine residue in the respiratory syncytial virus fusion protein cytoplasmic tail mediates assembly of internal viral proteins into viral filaments and particles.
    Shaikh FY; Cox RG; Lifland AW; Hotard AL; Williams JV; Moore ML; Santangelo PJ; Crowe JE
    mBio; 2012; 3(1):. PubMed ID: 22318318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Respiratory syncytial virus entry inhibitors targeting the F protein.
    Sun Z; Pan Y; Jiang S; Lu L
    Viruses; 2013 Jan; 5(1):211-25. PubMed ID: 23325327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-Induced Internalization of the Human Respiratory Syncytial Virus Fusion Protein.
    Leemans A; De Schryver M; Van der Gucht W; Heykers A; Pintelon I; Hotard AL; Moore ML; Melero JA; McLellan JS; Graham BS; Broadbent L; Power UF; Caljon G; Cos P; Maes L; Delputte P
    J Virol; 2017 Jul; 91(14):. PubMed ID: 28468888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease.
    Wiegand MA; Gori-Savellini G; Gandolfo C; Papa G; Kaufmann C; Felder E; Ginori A; Disanto MG; Spina D; Cusi MG
    J Virol; 2017 May; 91(10):. PubMed ID: 28250126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability.
    Zhang L; Durr E; Galli JD; Cosmi S; Cejas PJ; Luo B; Touch S; Parmet P; Fridman A; Espeseth AS; Bett AJ
    Vaccine; 2018 Dec; 36(52):8119-8130. PubMed ID: 30340881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.